ReviewPathogens (Basel, Switzerland)2015
Interleukin 17-Mediated Host Defense against Candida albicans.
Review in Pathogens (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- The molecular mechanism of the adverse effects of the biological and small molecular drugs in the therapy of inflammatory skin diseases - psoriasis and atopic dermatitis.Annals of medicine · 2026Review
- Postmarketing reporting patterns of Candida-related events associated with bimekizumab and selective IL-17A inhibitors in psoriasis: a FAERS and JADER pharmacovigilance study.Frontiers in pharmacology · 2026Article
- The PP2A Catalytic Subunit PPH21 Regulates Biofilm Formation and Drug Resistance ofMicroorganisms · 2025Article
- Interstitial pneumonia via the oropharyngeal route of infection with Encephalitozoon cuniculi.PLoS neglected tropical diseases · 2025Article
- Inflammatory cytokine signalling in vulvovaginal candidiasis: a hot mess driving immunopathology.Oxford open immunology · 2024Review
- Article
- Probiotics for Oral Candidiasis: Critical Appraisal of the Evidence and a Path Forward.Frontiers in oral health · 2022Review
- The Role of Group 3 Innate Lymphoid Cells in Lung Infection and Immunity.Frontiers in cellular and infection microbiology · 2021Review
- The Anti-Biofilm Efficacy of Caffeic Acid Phenethyl Ester (CAPE)Frontiers in cellular and infection microbiology · 2021Article
- STIM1-mediated calcium influx controls antifungal immunity and the metabolic function of non-pathogenic Th17 cells.EMBO molecular medicine · 2020Article
- Dermatophytosis in companion animals: A review.Veterinary world · 2020Review
- Biology of Interleukin-17 and Its Pathophysiological Significance in Sepsis.Frontiers in immunology · 2020Review
- Candida albicansmBio · 2019Article
- Article
- Persistence ofFrontiers in immunology · 2019Article
- Nystatin enhances the immune response against Candida albicans and protects the ultrastructure of the vaginal epithelium in a rat model of vulvovaginal candidiasis.BMC microbiology · 2018Article
- IL-22 neutralizing autoantibodies impair fungal clearance in murine oropharyngeal candidiasis model.European journal of immunology · 2018Article
- Modulation of the Fungal-Host Interaction by the Intra-Species Diversity of C. albicans.Pathogens (Basel, Switzerland) · 2018Review
- Patient Susceptibility to Candidiasis-A Potential for Adjunctive Immunotherapy.Journal of fungi (Basel, Switzerland) · 2018Review
- Recurrent candidal intertrigo: challenges and solutions.Clinical, cosmetic and investigational dermatology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Candida albicans is part of the normal microbiota in most healthy individuals. However, it can cause opportunistic infections if host defenses are breached, with symptoms ranging from superficial lesions to severe systemic disease. The study of rare congenital defects in patients with chronic mucocutaneous candidiasis led to the identification of interleukin-17 (IL-17) as a key factor in host defense against mucosal fungal infection. Experimental infections in mice confirmed the critical role of IL-17 in mucocutaneous immunity against C. albicans. Research on mouse models has also contributed importantly to our current understanding of the regulation of IL-17 production by different cellular sources and its effector functions in distinct tissues. In this review, we highlight recent findings on IL-17-mediated immunity against C. albicans in mouse and man.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.